Treatment with luspatercept-aamt (Reblozyl) reduced the severity of anemia in patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts who require red blood cell (RBC) transfusions, according to findings from the phase III MEDALIST trial that have now been published in the New England Journal of Medicine (NEJM).
Research presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) had a significant effect on the standard of care for patients with HER2-positive metastatic breast cancer, explained Erika P. Hamilton, MD.
The FDA has granted a priority review for the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer.
We asked our audience about what kind of cancer advancements they wish to see in the next 10 years. Here’s what they had to say.
The standard of care for treatment-naïve patients with advanced renal cell carcinoma (RCC) has shifted from a single-agent VEGF TKI to a checkpoint inhibitor plus either a VEGF TKI or a CTLA-4 inhibitor, explained David F. McDermott, MD.
Novel next-generation imaging modalities have greater visibility than conventional imaging tools, leading to higher detection rates and earlier treatment of early recurrences and metastatic disease among men with prostate cancer, explained Hussein Aoun, MD.
See what your peers voted to be the top cancer advancements of the decade!
The FDA has approved avapritinib (Ayvakit) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.
Frequent communication between patients and providers is key in getting ahead of adverse events that can occur during breast cancer treatment, explained Madeline Kuiper, MSN, RN, OCN, an oncology nurse practitioner at UCLA.
The approval of several TKIs and combination regimens has led to more treatment options for patients with renal cell carcinoma (RCC), with a heavier focus on individualized approaches, explained Ajjai Shivaram Alva, MBBS.
The FDA approved pembrolizumab (Keytruda) for the treatment of patients who are unresponsive to Bacillus Calmette-Guerin (BCG) treatment with high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Not taking opioids as prescribed can be extremely risky to patients, but oncology nurses can help.
The metastatic pancreatic cancer paradigm has expanded to include frontline maintenance therapy with the PARP inhibitor olaparib (Lynparza), as it recently received the green light from the FDA with a December 2019 approval.
The combination of itacitinib and corticosteroids did not induce a statistically significant improvement in overall response rate (ORR) at day 28 compared with placebo plus corticosteroids in patients with treatment-naïve acute graft-versus-host disease (aGVHD).
An expert discusses lung cancer advances from 2020, as well as exciting new research that is underway.
The FDA has accepted a biologics license application (BLA) to review eflapegrastim (Rolontis) for the management of chemotherapy-induced neutropenia, according to Spectrum Pharmaceuticals, the developer of the novel long-acting granulocyte-colony stimulating factor (G-CSF).
Not all patients with advanced non–small cell lung cancer (NSCLC) are recommended for genomic testing when treated in a community setting, and are therefore not being appropriately tested for potential molecular drivers of their disease, explained Nathan Pennell, MD, PhD.
There is still a lack of clear biomarkers in the metastatic renal cell carcinoma space.
We want to hear from you about what you think were the top cancer advances of the last 10 years.
The FDA has accepted a biologics license application (BLA) for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer (TNBC) who have received at least 2 prior therapies for metastatic disease, according to a statement from the company developing the antibody-drug conjugate (ADC), Immunomedics.
After decades of few advances and stagnant treatment approaches, which mainly comprised 7+3 chemotherapy, the acute myeloid leukemia (AML) paradigm now has several agents approved, and plenty of ongoing trials are exploring other novel therapies alone and in combination, according to Melissa L. Larson, MD.
The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma.
The year – and the decade – are coming to a close. Look back with us at the top web articles of 2019.
The approval of novel agents, specifically blinatumomab (Blincyto) and CAR T-cell therapy, in the acute lymphoblastic leukemia (ALL) paradigm has led has to expanded options for pediatric, adolescent and young adult (AYA), and adult patients; however, ongoing trials are poised to keep moving the field forward, said Joseph Wynne, MD.
A biologics license application has been submitted to the FDA for the rituximab (Rituxan) biosimilar ABP 798, according to the developers, Amgen and Allergan
The FDA has approved the use of Trastuzumab Deruxtecan for the treatment of patients with HER2+ Breast Cancer, based on recent findings.
Three pivotal trials demonstrating improved metastasis-free survival (MFS) with 3 different oral antiandrogen agents in combination with androgen deprivation therapy (ADT) have led to FDA approvals that have transformed the treatment paradigm in nonmetastatic castration-resistant prostate cancer (CRPC), said Elisabeth I. Heath, MD, FACP.
Nurses tend to sleep less before a shift, which could impact patient care, according to recent research conducted at NYU Rory Meyers College of Nursing.
The FDA has granted tucatinib a breakthrough therapy designation for use in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, who had prior trastuzumab, pertuzumab (Perjeta), and ado-trastuzumab emtansine (T-DM1; Kadcyla).
